Most doses of Eli Lilly’s Zepbound, Mounjaro in short supply through June, FDA says 

The insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.

Previous post Sage Therapeutics’ stock plunges as Parkinson’s drug trial disappoints
Next post Morgan Stanley reportedly planning four-part bond deal a day after blowout earnings